Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA® (tucatinib) in ...
TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study The combination demonstrated a ...
Fewer than half of eligible advanced ovarian cancer patients receive first-line maintenance treatment, despite available options like bevacizumab and PARP inhibitors. The study found 48.2% of patients ...
The combination of tarlatamab and standard anti-PD-L1 therapy as first-line maintenance therapy led to “unprecedented” survival gains among patients with extensive-stage small cell lung cancer ...
The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according to the agent’s manufacturer. Lurbinectedin (Zepzelca; Jazz Pharmaceuticals, PharmaMar) is ...
The addition of lurbinectedin — a novel alkylating agent and transcription inhibitor — to first-line maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC) improved survival ...
– Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte study – – First and only combination therapy for the first-line maintenance ...
The IMforte trial showed Zepzelca plus Tecentriq improved progression-free and overall survival in extensive-stage SCLC, suggesting a new first-line maintenance standard. DELPHI-304 demonstrated ...
The FDA accepted Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer, granting priority review. Phase 3 IMforte trial showed Zepzelca plus Tecentriq improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback